Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus nab-paclitaxel and carboplatin for unresectable cancer of unknown primary
ChiCTR2400079592Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, paclitaxel and carboplatin in cancer of unknown primary (CUP), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Objective response rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
tislelizumabpaclitaxelcarboplatin
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on ChiCTR2400079592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079592.